NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies attracting international attention in 2026.
A report published by Medical Design & Outsourcing on October 9, 2026, titled “The most innovative medical devices of 2026”, identifies 23 medical technologies nominated in the Best Medical Technology category of the 2026 Prix Galien USA awards. The nominations span several medical specialties, from cardiovascular disease and cancer to hearing loss, urinary incontinence and respiratory disorders.
The Prix Galien programme recognises advances in medical science and healthcare innovation. The US medical technology category requires nominated devices to have received US Food and Drug Administration (FDA) approval within the preceding five years. Previous nominations do not necessarily indicate a new approval or a new clinical breakthrough in 2026. The 2026 US awards ceremony is scheduled for October 29 in New York.
Cardiac technologies seek to improve treatment outcomes
Several nominees address cardiovascular conditions requiring sophisticated interventions.
Abbott’s Aveir dual-chamber leadless pacemaker is designed to provide coordinated pacing without the conventional implanted pacemaker system’s chest pocket and transvenous leads. Its Esprit BTK everolimus-eluting resorbable scaffold targets below-the-knee peripheral artery disease, while the TriClip G4 system offers a catheter-based approach to repairing the tricuspid valve.
Edwards Lifesciences’ Sapien M3 transcatheter mitral valve replacement system represents another significant development in catheter-based heart-valve intervention. The approach aims to treat mitral valve disease without conventional open-heart surgery in appropriately selected patients.
Johnson & Johnson MedTech’s Impella CP and Impella 5.5 heart pumps provide temporary mechanical circulatory support in selected patients with severe cardiac dysfunction. Its Shockwave C2 coronary catheter uses intravascular lithotripsy to modify calcified plaque and facilitate coronary intervention.
These technologies illustrate the continuing shift towards less invasive procedures, although their suitability depends on individual patient characteristics, clinical evidence and the approved indications for use.
Cancer diagnosis and treatment move towards precision medicine
Cancer-related technologies feature prominently in the nominations. Guardant Health’s Guardant360 liquid biopsy test and Shield colorectal cancer screening blood test represent two different applications of blood-based testing. Liquid biopsy can help inform cancer treatment decisions in appropriate settings, while blood-based screening offers a potential alternative to conventional screening approaches for eligible patients.
LumiCell’s LumiSystem is designed to highlight residual breast tumour cells during surgery, potentially helping surgeons identify tissue that requires further assessment. Johnson & Johnson’s Inlexzo is an intravesical drug-delivery implant designed to provide sustained release of gemcitabine for bladder cancer.
RefleXion Medical’s X1 linear accelerator with SCINTIX technology combines positron emission tomography (PET) information with radiation treatment to support the targeting of selected tumours. The objective is to improve treatment precision by incorporating information about tumour biology into radiotherapy delivery.
Neurological, respiratory and hearing innovations
Insightec’s Exablate Neuro uses focused ultrasound to perform incisionless brain procedures for selected patients with Parkinson’s disease and tremor. By concentrating ultrasound energy on a targeted area, the system can provide treatment without a conventional surgical incision.
Medtronic’s Altaviva tibial neuromodulation implant targets urinary incontinence through electrical stimulation of nerves involved in bladder control. Lungpacer Medical’s AeroPace transvenous diaphragm neurostimulator is designed to stimulate the diaphragm in selected patients requiring respiratory support.
Cochlear’s Nucleus Nexa internal hearing implant represents progress in implantable hearing technology, while Beyond Air’s LungFit PH generates nitric oxide without relying on conventional high-pressure gas cylinders, for use in its approved clinical setting.
Other nominees include Alcon’s Unity vitreoretinal and cataract surgery platform, Establishment Labs’ MRI-conditional Motiva Flora breast tissue expander, MiniMed’s Go smart insulin pen system and OUR United’s TaiChiPro radiosurgery and gamma-ray platform.
MediBeacon’s TGFR monitor is designed to measure kidney function in real time, potentially supporting clinical assessment where conventional laboratory measurements provide less immediate information.
Global regulatory oversight remains essential
The international significance of these technologies extends beyond award nominations. Their clinical adoption depends on the quality of supporting evidence, manufacturing standards, regulatory authorisation and post-market safety monitoring.
The US FDA regulates medical devices through risk-based pathways, including premarket approval, De Novo classification and 510(k) clearance, depending on the device and its characteristics. Its updated Quality Management System Regulation became effective on February 2, 2026, incorporating ISO 13485:2016 into the US device quality framework. FDA: Overview of Device Regulation.
In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees medical-device safety and market access. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) undertakes scientific reviews supporting regulatory decisions, while Australia’s Therapeutic Goods Administration (TGA) regulates medical devices according to risk classification and applicable registration requirements. China’s National Medical Products Administration (NMPA) and India’s Central Drugs Standard Control Organisation (CDSCO) also oversee medical-device regulation within their respective jurisdictions.
These agencies operate under different legal frameworks. A device’s US FDA authorisation or Prix Galien nomination must not be interpreted as automatic approval for marketing in the UK, Japan, Australia, China or India.
For India, the regulatory status of an individual device must be checked against the applicable provisions of the Medical Devices Rules, 2017, and relevant CDSCO approvals or registration requirements. Internationally recognised innovation may provide useful evidence for evaluation, but it does not replace local regulatory scrutiny.
Innovation must translate into patient benefit
The 2026 nominations demonstrate how medical-device development is increasingly focused on less invasive interventions, targeted treatment, improved monitoring and earlier disease detection. Yet technological sophistication alone cannot establish clinical superiority.
Independent evidence must demonstrate whether these devices improve meaningful patient outcomes, reduce complications, shorten hospital stays or provide better value than existing alternatives. Their costs, maintenance requirements, training needs and availability will also influence adoption, particularly in resource-constrained healthcare systems.
For India, the challenge is to ensure that promising technologies become accessible without compromising patient safety or imposing unsustainable costs on hospitals and patients. Transparent procurement, specialist evaluation, robust clinical evidence and continued adverse-event surveillance are essential to achieving that balance.
The Prix Galien nominations therefore offer a snapshot of medical technology development in 2026—not a definitive ranking of the world’s best devices. Their ultimate value will depend on demonstrated clinical benefit, appropriate regulatory authorisation and equitable access.
Source : Medical Design & Outsourcing
